Viral vectors for gene delivery to the central nervous system

被引:179
作者
Lentz, Thomas B. [1 ]
Gray, Steven J. [1 ]
Samulski, R. Jude [1 ]
机构
[1] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA
关键词
Viral vectors; Central nervous system; Gene therapy; Adeno-associated virus; Retrovirus; Adenovirus; Herpesvirus; HERPES-SIMPLEX-VIRUS; RECOMBINANT ADENOASSOCIATED VIRUS; INTEGRATING LENTIVIRAL VECTORS; MEDIATED TRANSGENE EXPRESSION; VESICULAR STOMATITIS-VIRUS; CELL-SURFACE RECEPTORS; IMMEDIATE-EARLY GENES; PHASE-I TRIAL; ADENOVIRAL VECTOR; HELPER VIRUS;
D O I
10.1016/j.nbd.2011.09.014
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The potential benefits of gene therapy for neurological diseases such as Parkinson's, Amyotrophic Lateral Sclerosis (ALS), Epilepsy, and Alzheimer's are enormous. Even a delay in the onset of severe symptoms would be invaluable to patients suffering from these and other diseases. Significant effort has been placed in developing vectors capable of delivering therapeutic genes to the CNS in order to treat neurological disorders. At the forefront of potential vectors, viral systems have evolved to efficiently deliver their genetic material to a cell. The biology of different viruses offers unique solutions to the challenges of gene therapy, such as cell targeting, transgene expression and vector production. It is important to consider the natural biology of a vector when deciding whether it will be the most effective for a specific therapeutic function. In this review, we outline desired features of the ideal vector for gene delivery to the CNS and discuss how well available viral vectors compare to this model. Adeno-associated virus, retrovirus, adenovirus and herpesvirus vectors are covered. Focus is placed on features of the natural biology that have made these viruses effective tools for gene delivery with emphasis on their application in the CNS. Our goal is to provide insight into features of the optimal vector and which viral vectors can provide these features. (c) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 199 条
[81]   AAV Recombineering with Single Strand Oligonucleotides [J].
Hirsch, Matthew L. ;
Storici, Francesca ;
Li, Chengwen ;
Choi, Vivian W. ;
Samulski, Jude .
PLOS ONE, 2009, 4 (11)
[82]   PARTIAL-PURIFICATION OF ADENOASSOCIATED VIRUS REP78, REP52, AND REP40 AND THEIR BIOCHEMICAL-CHARACTERIZATION [J].
IM, DS ;
MUZYCZKA, N .
JOURNAL OF VIROLOGY, 1992, 66 (02) :1119-1128
[83]   THE AAV ORIGIN BINDING-PROTEIN REP68 IS AN ATP-DEPENDENT SITE-SPECIFIC ENDONUCLEASE WITH DNA HELICASE ACTIVITY [J].
IM, DS ;
MUZYCZKA, N .
CELL, 1990, 61 (03) :447-457
[84]   AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma:: A randomised, controlled study [J].
Immonen, A ;
Vapalahti, M ;
Tyynelä, K ;
Hurskainen, H ;
Sandmair, A ;
Vanninen, R ;
Langford, G ;
Murray, N ;
Ylä-Herttuala, S .
MOLECULAR THERAPY, 2004, 10 (05) :967-972
[85]   Persistence of High-Capacity Adenoviral Vectors as Replication-Defective Monomeric Genomes In Vitro and in Murine Liver [J].
Jager, Lorenz ;
Ehrhardt, Anja .
HUMAN GENE THERAPY, 2009, 20 (08) :883-896
[86]   Lentiviral vectors for use in the central nervous system [J].
Jakobsson, J ;
Lundberg, C .
MOLECULAR THERAPY, 2006, 13 (03) :484-493
[87]   Efficient transduction of neurons using Ross River glycoprotein-pseudotyped lentiviral vectors [J].
Jakobsson, J. ;
Nielsen, T. Tolstrup ;
Staflin, K. ;
Georgievska, B. ;
Lundberg, C. .
GENE THERAPY, 2006, 13 (12) :966-973
[88]  
Johnson MC, 2011, AIDS RES HUM RETROV, V27, P239, DOI [10.1089/aid.2010.0350, 10.1089/AID.2010.0350]
[89]   A packaging cell line for lentivirus vectors [J].
Kafri, T ;
van Praag, H ;
Ouyang, L ;
Gage, FH ;
Verma, IM .
JOURNAL OF VIROLOGY, 1999, 73 (01) :576-584
[90]   Notable Reduction in Illegitimate Integration Mediated by a PPT-deleted, Nonintegrating Lentiviral Vector [J].
Kantor, Boris ;
Bayer, Matthew ;
Ma, Hong ;
Samulski, Jude ;
Li, Chengwen ;
McCown, Thomas ;
Kafri, Tal .
MOLECULAR THERAPY, 2011, 19 (03) :547-556